CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong
· Delayed Price · Currency is HKD 0.1620
+0.0260 (19.12%)
Jun 2, 2025, 3:59 PM HKT
CANbridge Pharmaceuticals Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 10.5 | 137.49 | 463.11 | 745.82 | 360.8 | Upgrade
|
| Cash & Short-Term Investments | 10.5 | 137.49 | 463.11 | 745.82 | 360.8 | Upgrade
|
| Cash Growth | -92.36% | -70.31% | -37.91% | 106.71% | 2500.76% | Upgrade
|
| Accounts Receivable | 16.72 | 31.23 | 19.05 | 9.14 | 7.04 | Upgrade
|
| Other Receivables | 9.87 | 8.29 | - | 18.76 | 8.77 | Upgrade
|
| Receivables | 26.59 | 39.52 | 19.05 | 27.9 | 25.01 | Upgrade
|
| Inventory | 7.9 | 8.78 | 9.82 | 13.45 | 0.55 | Upgrade
|
| Other Current Assets | 0.36 | 24.08 | 13.18 | 24.54 | 4.68 | Upgrade
|
| Total Current Assets | 45.35 | 209.86 | 505.16 | 811.71 | 391.05 | Upgrade
|
| Property, Plant & Equipment | 3.64 | 109.01 | 144.72 | 29.54 | 15.57 | Upgrade
|
| Other Intangible Assets | 67.82 | 76.49 | 49.01 | 51.27 | 179.74 | Upgrade
|
| Other Long-Term Assets | - | - | 3.16 | - | - | Upgrade
|
| Total Assets | 116.81 | 395.36 | 702.05 | 892.52 | 586.36 | Upgrade
|
| Accounts Payable | 370.46 | 198.05 | 107.54 | 43.61 | 46.71 | Upgrade
|
| Accrued Expenses | 68.7 | 63.46 | 114.98 | 93.82 | 23.91 | Upgrade
|
| Current Portion of Long-Term Debt | 15.33 | 23.69 | 26.87 | 30.87 | 22.31 | Upgrade
|
| Current Portion of Leases | 11.76 | 11.03 | 13.03 | 7.88 | 5.52 | Upgrade
|
| Other Current Liabilities | 16.37 | 31.71 | 15.69 | 9.6 | 9.65 | Upgrade
|
| Total Current Liabilities | 482.61 | 327.95 | 278.11 | 185.78 | 108.1 | Upgrade
|
| Long-Term Debt | 15.04 | 6.63 | 10.78 | - | 2,179 | Upgrade
|
| Long-Term Leases | 93.65 | 100.58 | 104.61 | 13.35 | 7.42 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 37.93 | Upgrade
|
| Total Liabilities | 591.3 | 435.15 | 393.49 | 199.13 | 2,332 | Upgrade
|
| Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 3,474 | 3,473 | 3,471 | 3,471 | 26.36 | Upgrade
|
| Retained Earnings | -4,210 | -3,789 | -3,411 | -2,927 | -1,850 | Upgrade
|
| Comprehensive Income & Other | 261.79 | 276.55 | 247.88 | 149.89 | 77.9 | Upgrade
|
| Shareholders' Equity | -474.49 | -39.79 | 308.56 | 693.39 | -1,746 | Upgrade
|
| Total Liabilities & Equity | 116.81 | 395.36 | 702.05 | 892.52 | 586.36 | Upgrade
|
| Total Debt | 135.78 | 141.93 | 155.28 | 52.1 | 2,214 | Upgrade
|
| Net Cash (Debt) | -125.28 | -4.44 | 307.83 | 693.71 | -1,853 | Upgrade
|
| Net Cash Growth | - | - | -55.63% | - | - | Upgrade
|
| Net Cash Per Share | -0.29 | -0.01 | 0.73 | 7.36 | -27.02 | Upgrade
|
| Filing Date Shares Outstanding | 424.56 | 424.56 | 424.29 | 424.19 | 469.11 | Upgrade
|
| Total Common Shares Outstanding | 424.56 | 424.56 | 424.29 | 424.19 | 73.56 | Upgrade
|
| Working Capital | -437.26 | -118.08 | 227.06 | 625.93 | 282.94 | Upgrade
|
| Book Value Per Share | -1.12 | -0.09 | 0.73 | 1.63 | -23.73 | Upgrade
|
| Tangible Book Value | -542.31 | -116.28 | 259.54 | 642.12 | -1,926 | Upgrade
|
| Tangible Book Value Per Share | -1.28 | -0.27 | 0.61 | 1.51 | -26.18 | Upgrade
|
| Machinery | 10.68 | 16.58 | 13.54 | 4.79 | 3.75 | Upgrade
|
| Leasehold Improvements | 1.94 | 3.94 | 10.86 | 11.32 | 5.11 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.